Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: food

Digital therapy outperforms referrals to campus clinics among college students

College students with anxiety, depression and eating disorders may be more likely to start and to respond more positively to therapy offered via a digital app compared to referrals to in-person campus clinics, according to a study led by Penn State researchers and published in the journal Nature Human Behaviour.

Globally, an estimated 40% to 60% of college students experience a mental health disorder at some point, and the need for campus counseling services has increased faster than institutions’ capacity to provide these services, according to the researchers.

The research team wanted to see if a proactive intervention using a digital therapy app could effectively treat anxiety disorders, depression and eating disorders, as well as address the increased need for psychological services.

Harmless viruses trap Salmonella on flexible polymer in portable microfluidic sensor

Researchers at Worcester Polytechnic Institute (WPI) have developed a solid polymer coated with harmless viruses to detect the bacteria Salmonella enterica (S. enterica), an advance that could lead to new ways of finding contamination in the food supply. The work is published in the journal ACS Applied Bio Materials.

The group, led by Yuxiang “Shawn” Liu, an associate professor in the Department of Mechanical and Materials Engineering, reports that the technology can rapidly capture and visualize foodborne bacterial contaminants in tiny fluid samples. With no need for incubation or complicated equipment in research centers, the technology has the potential to be used as a rapid biosensor in field applications and in areas with few resources.

“We have a solid surface that can be used anywhere in the food supply chain, from farm to fridge, to detect foodborne bacteria with minimum human intervention,” Liu says.

FDA Approves Novel Weekly Basal Insulin for T2D

The FDA has approved once-weekly insulin icodec-abae (Awiqli; Novo Nordisk) for use in adults with type 2 diabetes (T2D), with a current projected launch in the second half of 20,261 for the 700-units/mL dose. This novel treatment option is a first-in-its-class therapeutic, freeing patients living with T2D from their strict schedule of daily basal insulin injections and reducing total injections from 7 to 1 for each 7-day period.

Its indication is as an adjunct to diet and exercise for improved glycemic control, as well as for patients also taking mealtime insulin or another common oral antidiabetic agent and/or a glucagon-like peptide-1 receptor agonist. A prescription is required, and administration is with or without food via a prefilled FlexTouch device on the same day each week.

Data from 4 of the trials in the phase 3a ONWARDS program and 2,680 adult patients with uncontrolled T2D support this approval; their primary end point of interest was reduction in hemoglobin A1c. Overall, the ONWARDS program encompasses 6 phase 3a trials and more than 4,000 adults with type 1 diabetes (T1D) or T2D.

Insulin icodec-abae (Awiqli; Novo Nordisk) is now approved for use in the US, Canada, European Union, Switzerland, and 12 other countries.

A brain reward circuit inhibited by next-generation weight-loss drugs in mice

New research using humanized mouse models has finally pulled back the curtain on how these small-molecule drugs work in the brain, revealing that they don’t just tell the body it’s full—they actually change how we perceive “treats.”

1. The Homeostatic Circuit: This is the body’s fuel gauge. It involves the hypothalamus and hindbrain, which manage basic hunger and energy levels. It’s the circuit that tells you, “I’ve had enough calories for today.”

These new weight-loss pills do more than just settle your stomach; they speak directly to the brain’s reward center to help quiet the “food noise” that leads to overeating.

This is a “proof of concept” study. It proves the mechanism exists, but it doesn’t yet guarantee that a pill will be a side-effect-free “cure” for overeating in humans.

Humanized glucagon-like peptide 1 receptor (GLP1R) mouse models are used to investigate the neural circuitry through which small-molecule GLP1R agonists modulate feeding, with implications for how these orally delivered weight-loss drugs engage brain reward circuits.

New DNA-Based Therapy Can Help Lower ‘Bad Cholesterol’ Without Statins, Finds Study

Scientists may have found a powerful new way to lower “bad” cholesterol, which did not involve the use of statin medicines. In a recent study, researchers used tiny DNA-based molecules to cut levels of LDL (bad) cholesterol by nearly 50% in animal models. This was done without the side effects that are often linked to statins. If these results stay consistent in large human trials, the therapy could become an important option for people who cannot tolerate statins or who still have high cholesterol despite taking them. The study was led by Carles J. Ciudad and Veronica Noe from the University of Barcelona’s Faculty of Pharmacy and Food Sciences and the Institute of Nanoscience and Nanotechnology (IN2UB), working with Nathalie Pamir at the University of Oregon in Portland (United States). It was published in the journal Biochemical Pharmacology.

High LDL cholesterol is one of the biggest risk factors for heart attacks and strokes because it leads to the build up fatty plaques in arteries. Drugs like statins work well for many, but some people suffer from muscle aches, digestive issues, or liver problems and have to stop them. However, the new approach is different. Instead of changing how the liver handles fats, it targets a specific protein in the blood that controls how much LDL stays circulating.

Negative effects of artificial sweeteners may pass on to next-generation, study suggests

Health organizations are starting to raise concerns about the potential long-term impacts of artificial sweeteners, which taste sweet but—unlike sugar—contain no calories, suggesting they could interfere with energy metabolism and increase the eventual risk of diabetes or cardiovascular disease.

Now a new study in mice indicates that the popular sweeteners sucralose and stevia have negative effects on the gut microbiome and gene expression, potentially compromising metabolic health, which can be transmitted between generations.

“We found it intriguing that despite the growing consumption of these additives, the prevalence of obesity and metabolic disorders such as insulin resistance has not declined,” said Dr. Francisca Concha Celume of the Universidad de Chile, lead author of the article in Frontiers in Nutrition.

Direct electrochemical appraisal of black coffee quality using cyclic voltammetry

Coffee flavor is primarily determined by the bean roast color and concentration of the beverage. Here, the authors show that both of these characteristics are reflected in the coffee’s cyclic voltammogram. This approach enables rapid determination of the strength and roast intensity of the coffee.

Boosting good gut bacteria population through targeted interventions may slow cognitive decline

The origin of neurodegenerative diseases like Alzheimer’s or dementia isn’t limited to the brain. The state of your gut can quietly set off a cycle of chronic, system-wide inflammation that nudges the brain toward cognitive decline. But how does the pathogenesis of a disease that seems purely brain-based begin in the gut—an organ that is mostly busy producing chemicals for digesting food?

It turns out these two entities are linked by the gut-brain axis, a two-way communication superhighway that constantly sends signals between the digestive tract and the central nervous system. It runs on chemical messengers like neurotransmitters and fatty acids, sharing information that shapes our memory, mood, and inflammation triggers.

An analysis of 15 studies involving more than 4,200 participants found that the gut-brain highway can be put to work as a drug-free route to support cognitive health. Tuning the gut microbiota through diet, supplements, or medical interventions such as fecal microbiota transplantation (FMT) can help improve memory, executive function, and overall cognitive performance, particularly in early or mild cases of cognitive impairment.

Anaerobic digestion of poultry droppings for biogas production: a pilot study of renewable energy technology in the agricultural sector

Proper management of agricultural waste is challenging due to diverse sources, high production volumes, seasonal fluctuations, limited technical knowledge, and insufficient funding. These challenges often lead to soil degradation, environmental pollution, and adverse effects on ecosystems and human health. This study aims to investigate biogas production from poultry droppings using Continuous Stirred Tank Reactor (CSTR) Anaerobic Digestion (AD) technology to promote green energy use and as a sustainable solution for agricultural waste management.

Dried poultry manure samples were collected from two poultry farms in Lafia city and from their manure disposal sources. The samples were thoroughly stirred to ensure homogeneity and digested at a mesophilic temperature of 28.0 °C. With an initial solid concentration of 20.0%, the manure was diluted with water at 1:2 ratio to produce an input slurry containing 12.0% total volatile solids by weight. The experiment was conducted from July 20 to September 10, 2025. Parameters including pH, alkalinity, temperature, and biogas flow rate were monitored daily. Chemical and physical analyses of total solids, total volatile solids, and chemical oxygen demand were conducted during startup using three biological replicates (n = 3), with results expressed using statistical tool of mean ± standard error. Volatile fatty acids and alkalinity were measured using the distillation method.

For 74,000 years, one ancient killer quietly dictated where early humans could survive across Africa

Increasing evidence suggests that our species emerged through interactions between populations living in different parts of Africa, rather than from a single birthplace. Until now, however, most explanations for how those populations were distributed across the continent have focused on climate alone. The new research shows that disease—specifically malaria—also played a crucial role.

In a paper published in Science Advances, researchers from the Max Planck Institute of Geoanthropology, the University of Cambridge, and colleagues have investigated whether Plasmodium falciparum-induced malaria shaped human habitat choice between 74,000 and 5,000 years ago, the critical period before humans dispersed widely beyond Africa and before agriculture dramatically altered malaria transmission.

The study shows that malaria, one of humanity’s oldest and most persistent pathogens, influenced habitat choice by pushing human groups away from high-risk environments and separating populations across the landscape. Over tens of thousands of years, this fragmentation shaped how populations met, mixed, and exchanged genes, helping create the population structure seen in humans today. The findings suggest that infectious disease was not simply a challenge early humans faced: it was a fundamental factor shaping the deep history of our species.

/* */